Delivery Order 36F79724D0176-36C24526N0428
Award Date 3/20/26
Potential Completion Date 3/24/26
Potential Value $20K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Janssen Biotech Inc., a Johnson & Johnson subsidiary operating as Centocor Ortho Biotech Inc., was awarded a delivery order valued at $18,803.91 for BALVERSA 4 MG (erdafitinib), an oncology medication, by Veterans Integrated Service Network 5 (VISN 5) under the Department of Veterans Affairs. The firm fixed-price delivery order was awarded on September 25, 2025, with an ultimate completion date of September 29, 2025, and will be performed in Carrollton, Texas. This award carries no set-aside...
- Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., was awarded a firm fixed-price delivery order valued at $18,803.91 by Veterans Integrated Service Network 5 (VISN 5) on August 6, 2025, with an ultimate completion date of August 7, 2025. The contract covers the delivery of BALVERSA (erdafitinib), a specialized oncology medication, to the Veterans Health Administration facility in Carrollton, Texas. This delivery order carries no set-aside designation and is issued under the...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the pharmaceutical product BALVERSA 4MG TABS. The $17,642.95 order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract (FSS-61-IB) and has a completion date of June 30, 2024. Janssen Biotech Inc. is a for-profit manufacturer of specialty medications, including...
- Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., has been awarded a $17,642.95 firm fixed price delivery order for BALVERSA 4MG tablets from the Department of Veterans Affairs Veterans Health Administration (VHA) under the company's Pharmaceuticals and Drugs (FSS-61-IB) multiple award schedule contract. The delivery order, which has no set-aside designation and expires March 31, 2024, will provide cancer treatment medications to the VHA's Veterans Integrated Service Network...
- This is a firm fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order is valued at $18,125.50 and provides the VA's Veterans Health Administration (VHA) with the oncology medication BALVERSA (erdafitinib) to support healthcare services for veterans. The delivery order is placed against Janssen Biotech's existing $3.1 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $15,090.62 delivery order to Janssen Biotech, Inc. for BALVERSA 4 MG. The contract was issued against the Pharmaceuticals and Drugs Federal Supply Schedule, a multiple award schedule managed by the General Services Administration. Performance will take place in Carrollton, Texas. No set-aside designation was used for this firm fixed price order, which is scheduled for completion by...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $17,046 delivery order to Janssen Biotech, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The order is for BALVERSA 4MG and will be fulfilled from July 18-20, 2023 with performance taking place in Carrollton, Texas. Janssen Biotech will provide the specified oncology drug to VA-VHA under a firm fixed price arrangement. As one of the largest health care...
- Janssen Biotech, Inc. was awarded a $15,754.46 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The firm fixed price order is for the drug BALVERSA 4MG and has a period of performance through December 7, 2022. No set-aside provisions were applied to this award to supply prescription medications in support of healthcare...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $15,090.62 delivery order to Janssen Biotech, Inc. for BALVERSA 4 MG. The contract was issued against the Pharmaceuticals and Drugs Federal Supply Schedule, a multiple award schedule managed by the General Services Administration. Performance will take place in Carrollton, Texas. No set-aside provisions were applied to this firm fixed price order, which is scheduled for completion by...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...